Myokardia and fulcrum therapeutics announce multi-target collaboration to discover novel targeted therapies for genetic cardiomyopathies

Myokardia and fulcrum therapeutics announce multi-target collaboration to discover novel targeted therapies for genetic cardiomyopathies.fulcrum therapeutics inc - fulcrum will receive a payment of $12.5 million at close.fulcrum therapeutics - fulcrum may be eligible to receive milestone payments and additional research reimbursement of up to $302.5 million.fulcrum therapeutics inc - fulcrum may also be eligible to receive tiered royalty payments in mid-single-digit to low double-digit range.fulcrum therapeutics - if myokardia chooses commercialize products directed to additional targets, co may be eligible for up to $150.0 million in payments.
FULC Ratings Summary
FULC Quant Ranking